Hipolin

Why is Hipolin Ltd falling/rising?

As of 03-Aug, Hipolin Ltd's stock price is rising to 114.25, reflecting a 1.96% increase. This growth is driven by strong recent performance, increased promoter stake, and positive investor sentiment, despite some underlying concerns regarding long-term fundamentals.

As of 03-Aug, Hipolin Ltd's stock price is rising, currently at 114.25, reflecting a change of 2.2 (1.96%) upwards. This increase can be attributed to several factors. The stock has shown significant performance over the past week, with a rise of 10.35%, and an impressive 62.33% increase over the last month, far outpacing the Sensex, which only increased by 1.13% in the same period. Additionally, the stock has been on a consecutive gain streak for the last 19 days, accumulating a remarkable 63.52% return during this time.<BR><BR>Investor sentiment appears to be bolstered by rising promoter confidence, as the promoters have increased their stake in the company by 9.37% over the previous quarter, now holding 69.59% of the company. This increase in stake is often interpreted as a positive signal regarding the company's future prospects.<BR><BR>Moreover, Hipolin Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. The stock is also close to its 52-week high, just 2.35% away from Rs 116.93, further reflecting its bullish momentum.<BR><BR>However, it is important to note that there are underlying concerns, such as weak long-term fundamental strength and negative EBITDA, which could pose risks. Despite these issues, the current market performance and promoter confidence are driving the stock's rise at this time.

Which are the latest news on Hipolin?

Should I buy, sell or hold Hipolin Ltd?

How big is Hipolin?

As of 10th June, Hipolin Ltd has a market capitalization of 26.00 Cr and reported Net Sales of 14.15 Cr with a Net Profit loss of 0.72 Cr over the latest four quarters. The company has Shareholder's Funds of 8.14 Cr and Total Assets of 12.98 Cr.

As of 10th June, Hipolin Ltd has a market capitalization of 26.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Hipolin reported Net Sales of 14.15 Cr. However, the company experienced a loss of 0.72 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for Hipolin shows Shareholder's Funds of 8.14 Cr and Total Assets amounting to 12.98 Cr.

Who are in the management team of Hipolin?

The management team of Hipolin includes Chairman Shaileshkumar Jayantilal Shah, Executive Directors Daxesh B Shah, Samir Rohit Shah, Dimpal Sheth, and Independent Non-Executive Directors Nitaben Bharatbhai Shah, Ajay R. Gandhi, Umesh P. Mehta, and Avni Chouhan. This diverse team oversees the company's governance and strategic direction.

The management team of Hipolin includes the following members:<BR><BR>1. **Shaileshkumar Jayantilal Shah** - Chairman / Executive Director<BR>2. **Daxesh B Shah** - Executive Director<BR>3. **Samir Rohit Shah** - Executive Director<BR>4. **Dimpal Sheth** - Executive Director<BR>5. **Nitaben Bharatbhai Shah** - Independent Non-Executive Director<BR>6. **Ajay R. Gandhi** - Independent Non-Executive Director<BR>7. **Umesh P. Mehta** - Independent Non-Executive Director<BR>8. **Avni Chouhan** - Independent Non-Executive Director and Additional Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

Who are the peers of the Hipolin?

Hipolin's peers include Chordia Food, Spectrum Foods, Tyroon Tea Co., Kanco Tea, KMG Milk Food, Sonalis Consumer, Jay Kailash, Lake Shore, and Walpar Nutrition. In terms of performance, KMG Milk Food leads with a 1-year return of 10.72%, while Hipolin has a return of -8.57%.

Peers: The peers of Hipolin are Chordia Food, Spectrum Foods, Tyroon Tea Co., Kanco Tea, KMG Milk Food, Sonalis Consumer, Jay Kailash, Lake Shore, and Walpar Nutrition.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sonalis Consumer and Walpar Nutrition, while Average management risk is found at Spectrum Foods and Jay Kailash. Below Average management risk is noted for Chordia Food, Tyroon Tea Co., Kanco Tea, Hipolin, and the rest. For Growth, Excellent growth is seen at Sonalis Consumer, while Average growth is found at Jay Kailash, and Below Average growth is noted for Chordia Food, Spectrum Foods, Tyroon Tea Co., Kanco Tea, Hipolin, and the rest. In terms of Capital Structure, Good capital structure is present at Tyroon Tea Co., Sonalis Consumer, and Walpar Nutrition, while Below Average capital structure is observed at Chordia Food, Spectrum Foods, Kanco Tea, Hipolin, Jay Kailash, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is KMG Milk Food at 10.72%, while the lowest is Spectrum Foods at -50.76%. Hipolin's own 1-year return is -8.57%, which is higher than Spectrum Foods but lower than KMG Milk Food. Additionally, the six-month return is negative for Spectrum Foods, Kanco Tea, Sonalis Consumer, and Lake Shore.

What does Hipolin do?

Hipolin Ltd is a micro-cap company in the FMCG industry, incorporated in 1994, with recent quarterly net sales of 4 Cr and a net profit of 0 Cr as of March 2026. The company has a market cap of INR 26 Cr and key metrics include a debt-equity ratio of 0.05 and a return on equity of -10.69%.

Overview:<BR>Hipolin Ltd operates in the Fast-Moving Consumer Goods (FMCG) industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Hipolin was incorporated on 31 March 1994. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 4 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 26 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 45 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.05 <BR>Return on Equity: -10.69% <BR>Price to Book: 3.56<BR><BR>Contact Details:<BR>Address: A/1/1 Nilkanth Indus Estate, Sanand - Viramgam Highway Virochannagar Gujarat : 382170 <BR>Tel: 91-2717-284202 <BR>Email: hipolin@hipolin.com <BR>Website: http://www.hipolin.com

Are Hipolin Ltd latest results good or bad?

Hipolin Ltd's latest results are largely negative, showing a marginal net profit of ₹0.01 crore but a significant 25.40% decline in revenue year-on-year. With a troubling operating margin of -1.60% and a Mojo Score of 17, the company's financial health appears precarious, indicating ongoing challenges in the FMCG sector.

Hipolin Ltd's latest results present a mixed picture, but overall, they lean towards the negative side. In Q3 FY26, the company reported a net profit of ₹0.01 crore, which is a significant improvement of 101.75% year-on-year. However, this profit is marginal and reflects a wafer-thin PAT margin of just 0.27%, indicating that the company is barely profitable.<BR><BR>On the revenue front, Hipolin's sales were ₹3.76 crores, down 25.40% year-on-year, although there was a sequential improvement of 18.24% from the previous quarter. This decline in revenue, particularly following a severe drop of 50.53% in Q1 FY26, raises concerns about the company's ability to maintain sustainable growth.<BR><BR>The operating margin remains troubling at -1.60%, which signifies that the company is struggling to cover its basic operational costs. Additionally, the overall financial health of Hipolin is precarious, as evidenced by a Mojo Score of just 17 out of 100, categorizing it as a "Strong Sell." <BR><BR>The stock has also underperformed significantly, down 48.35% over the past year, which further illustrates the challenges the company faces in the competitive FMCG sector. Given these factors, while there is a slight improvement in net profit, the overall results indicate that Hipolin Ltd is still in a difficult position, making the latest results more bad than good.

When is the next results date for Hipolin Ltd?

The next results date for Hipolin Ltd is 14 February 2026.

The next results date for Hipolin Ltd is scheduled for 14 February 2026.

How has been the historical performance of Hipolin?

Hipolin's historical performance shows increasing net sales from 12.22 Cr in Mar'22 to 21.56 Cr in Mar'25, but rising expenditures have led to negative operating profits and a decline in profitability, with a profit before tax of -3.28 Cr in Mar'25. The company also faces challenges in cash flow, reporting -3.00 Cr from operating activities.

Answer:<BR>The historical performance of Hipolin shows a fluctuating trend in its financial metrics over the past four years.<BR><BR>Breakdown:<BR>Hipolin's net sales have increased from 12.22 Cr in Mar'22 to 21.56 Cr in Mar'25, indicating a positive growth trajectory. However, total expenditure has also risen significantly, from 13.46 Cr in Mar'22 to 24.88 Cr in Mar'25, leading to a negative operating profit (PBDIT) of -3.32 Cr in Mar'25, compared to -1.24 Cr in Mar'22. The company reported a profit before tax of -3.28 Cr in Mar'25, down from a profit of 7.63 Cr in Mar'23, reflecting a substantial decline in profitability. The total assets decreased from 16.28 Cr in Mar'24 to 12.98 Cr in Mar'25, while total liabilities also fell from 16.28 Cr to 12.98 Cr in the same period. Cash flow from operating activities has remained negative, with -3.00 Cr reported in Mar'25, indicating ongoing challenges in generating cash from operations. Overall, while Hipolin has shown growth in sales, it faces significant challenges in managing costs and profitability.

Is Hipolin overvalued or undervalued?

As of April 25, 2023, Hipolin is considered risky and overvalued due to its negative PE ratio of -8.55, poor returns on capital and equity, and significant underperformance compared to industry peers and the Sensex.

As of 25 April 2023, Hipolin's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial health. The company is currently overvalued, as evidenced by its negative PE ratio of -8.55 and an EV to EBITDA ratio of -8.97, which are starkly unfavorable compared to industry peers. Additionally, Hipolin's ROCE stands at -34.00% and ROE at -40.05%, reflecting substantial inefficiencies in generating returns.<BR><BR>In comparison to its peers, such as Hindustan Unilever with a PE ratio of 53.88 and Nestle India at 75.2, Hipolin's financial metrics are alarmingly poor. The EV to Sales ratio of 1.38 also suggests that investors are paying a premium for a company that is struggling to generate profits. Notably, Hipolin's stock has underperformed significantly against the Sensex, with a year-to-date return of -43.47% compared to the Sensex's 5.63%, reinforcing the perception of overvaluation.

What is the technical trend for Hipolin?

As of June 2, 2025, Hipolin's technical trend is mildly bearish, with mixed signals from various indicators, including bearish moving averages and Bollinger Bands, contrasted by some mildly bullish weekly indicators.

As of 2 June 2025, the technical trend for Hipolin has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands are bearish on both weekly and monthly charts, and daily moving averages also reflect a bearish trend. The KST shows a mildly bullish weekly outlook but is mildly bearish monthly, and Dow Theory indicates a mildly bearish weekly stance with a mildly bullish monthly view. The OBV is mildly bearish weekly but bullish monthly, adding to the mixed signals. Overall, the current technical stance is mildly bearish, driven primarily by bearish moving averages and Bollinger Bands, despite some mildly bullish indicators on the weekly time frame.

Who are the top shareholders of the Hipolin?

The top shareholder of Hipolin is Kinnari Vaibhav Shah, owning 18.75%, with promoters holding a total of 39.76% pledged shares. Public shareholders include Arunaben Manherlal Vakil at 1.65%, while individual investors collectively hold 23.17%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Hipolin primarily consist of promoters, with Kinnari Vaibhav Shah holding the largest share at 18.75%. The promoters collectively have a pledged holding of 39.7627%. In terms of public shareholders, Arunaben Manherlal Vakil is the highest individual shareholder, owning 1.65%. Additionally, individual investors collectively hold 23.17% of the company. Notably, there are currently no mutual funds or foreign institutional investors (FIIs) holding shares in Hipolin.

Has Hipolin declared dividend?

Hipolin Ltd has declared a 10% dividend, amounting to 1.0000 per share, but the dividend yield is 0%. While recent short-term returns are negative, long-term returns have shown significant growth.

Hipolin Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1.0000<BR>- Ex-date: Sep-23-2010<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -48.32%, the dividend return was 0%, resulting in a total return of -48.32%.<BR><BR>For the 1-year period, the price return was -29.69%, the dividend return was 0%, leading to a total return of -29.69%.<BR><BR>Over the 2-year period, the price return was -2.0%, the dividend return was 0%, which resulted in a total return of -2.0%.<BR><BR>In the 3-year period, the price return was 139.02%, the dividend return was 0%, culminating in a total return of 139.02%.<BR><BR>For the 4-year period, the price return was 159.41%, the dividend return was 0%, resulting in a total return of 159.41%.<BR><BR>In the 5-year period, the price return was 375.47%, the dividend return was 0%, leading to a total return of 375.47%.<BR><BR>Overall, while Hipolin Ltd has declared a dividend, the dividend yield is 0%, indicating that the dividend does not contribute to the returns in recent periods. The total returns show significant fluctuations, with strong positive returns over longer periods despite negative returns in the short term.